https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Tohoku J. Exp. Med. 2006 Jan;208(1):1-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Tohoku J. Exp. Med. 2006 Jan;208(1):1-82006-01-01 00:00:002019-02-15 08:44:43Genetically modified dendritic cells for therapeutic immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Cytotherapy 2006;8(4):318-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Cytotherapy 2006;8(4):318-262006-01-01 00:00:002019-02-15 08:45:56Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Cytotherapy 2006;8(3):277-89
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Cytotherapy 2006;8(3):277-892006-01-01 00:00:002019-02-15 08:51:01Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Clin. Exp. Immunol. 2005 Dec;142(3):555-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Clin. Exp. Immunol. 2005 Dec;142(3):555-682005-12-01 00:00:002019-02-15 08:49:34Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Pathology 2005 Dec;37(6):534-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Pathology 2005 Dec;37(6):534-502005-12-01 00:00:002019-02-15 08:51:27Vaccine strategies to treat lymphoproliferative disorders
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-15 / Immunol. Lett. 2006 Mar;103(2):142-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-15 / Immunol. Lett. 2006 Mar;103(2):142-82005-11-15 00:00:002005-11-15 00:00:00Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6B):4225-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6B):4225-302005-11-01 00:00:002019-02-15 08:53:28Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3771-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3771-62005-11-01 00:00:002019-02-15 08:44:45Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-24 / Gynecol Oncol 2006 Mar;100(3):469-78
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-24 / Gynecol Oncol 2006 Mar;100(3):469-782005-10-24 00:00:002023-01-23 10:35:21HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-01 / Zhonghua Xue Ye Xue Za Zhi 2005 Oct;26(10):593-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-01 / Zhonghua Xue Ye Xue Za Zhi 2005 Oct;26(10):593-72005-10-01 00:00:002019-02-15 08:51:02[In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine]
